Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Ultragenyx doses first patient in DTX401 Phase 1/2 study to treat GSDIa

Go Top